Ad
Thursday, 1 December 2016
Merck wins UK okay for Keytruda in lung cancer after price cut
LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment